CAR-BCMA(Sheba Medical Center)

N/A

Report date: 2022/03/11 10:50:18

Base Information

Drug NameCAR-BCMA(Sheba Medical Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSheba Medical Center, Israel

China Registration ClassN/A

Develop Information

Active CompaniesSheba Medical Center, Israel

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A